Three companion animal earnings reports in three days, and they do not agree

The growth is real. The bill arrives in Q3

Two things are true at once, and the order you read them in changes the conclusion. Against last year, margin expanded, from 19.2% to 21.2%. Against last quarter, it stepped down, from 24.5% to 21.2%. The year-over-year number says the business is structurally healthier than it was. The sequential number says this particular quarter carried more cost than the one before it.

What settles it is the guidance. The company has told the market to expect Q3 operating expenses up around 10% year over year in constant currency, with incremental support for innovation products. Read alongside Pet Health organic growth going from 7% to 11%, that is a business choosing to spend into a window rather than bank the margin.

If you compete here, plan for presence rather than price. Money going into launch support shows up as field coverage and promotional weight in accounts you already hold. It does not usually show up as discounting.

Traces to: Pet Health organic 7% to 11%; adjusted EBITDA margin 21.2% against 19.2% a year earlier and 24.5% in Q1; Q3 operating expense guidance of approximately 10% growth in constant currency with incremental support for innovation products.

The land grab worked, and it is nearly finished

The question going into this quarter was whether the combination parasiticide was still winning new clinics or only selling deeper into the ones it had. The clinic base moved from over 40% to over 50% in a single quarter, so the answer is new clinics. Breadth is still being won.

That also sets the ceiling. Once a product is in more than half the clinic base, the next leg of growth has to come from depth: more patients per clinic, better reorder rates, longer courses. Depth is a different commercial motion and a slower one. Expect the story to shift from how many clinics carry it to how much each one uses.

Traces to: US clinic base over 40% at Q1 to over 50% at Q2, company-stated; 53% share within clinics carrying it at Q1, Kynetec-reported.

The market did not shrink. Share moved

Three companion animal businesses reported within three days. One grew 11% organically, one grew 5%, and the largest declined 6% with the United States down 11%. A market in broad decline does not produce that spread. Two companies growing while the biggest one falls is share changing hands.

Be careful with the conclusion, because the largest company gives four causes and only two of them are competitive. It names continued softer end-market demand and pet owner price sensitivity, which are market conditions. It also names heightened competition in key categories, and generic competition on two brands plus lower sales of one further named product, which are not. Anyone claiming this quarter proves pure share transfer is reading half the sentence.

What the spread does establish is that demand alone cannot explain it. If the companion animal market were simply soft, three companies selling into the same clinics would not post plus 11, plus 5 and minus 6. Softness is real and it is not distributed evenly, which is another way of saying some of it is competitive.

One category is worth separating out. Elanco's combination parasiticide moved from over 40% to over 50% of the United States clinic base, and the combination parasiticide category is one of the two Zoetis names as under pressure. That is the clearest single line between one company's gain and another's loss on this page. Elanco's other gaining product will not give you the same line: its disclosure changed shape between quarters, from use in over 50% of United States clinics at Q1 to approximately 18,000 United States clinics at Q2. Those are two different metrics, so no like-for-like movement can be computed from them, and neither figure is a share of anything.

For your planning, the diagnostic question is which mix you are living through, because the responses are opposites. A demand problem calls for patience and cost discipline. A share problem calls for urgency. Generic erosion calls for neither, it calls for a different portfolio conversation.

Traces to: Elanco Pet Health 11% organic; Merck companion animal 5% excluding foreign exchange; Zoetis Companion Animal minus 6% organic operational and United States minus 11%; the four Zoetis-stated causes listed in the sources note above, including generic competition on two brands and lower sales of one further named product; Elanco combination parasiticide clinic base over 40% to over 50%; Elanco's other named product disclosed as over 50% of US clinics at Q1 and approximately 18,000 US clinics at Q2.